Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 8;8:740154. doi: 10.3389/fmed.2021.740154

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Huang, Zhu, Ye, Wu, Yan, Wang, Lin and Chen.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

CMV infection differences between MDA5⁺DM and MDA5⁻ IIM patients. (A) Levels of CMV-IgM in MDA5⁺DM and MDA5⁻ IIM patients; Levels of CMV-IgM were increased in MDA5⁺DM compared with MDA5⁻ IIM patients (8 U/mL, IQR 5–14 U/mL vs. 6 U/mL, IQR 5–10 U/mL, p = 0.039). (B) The percentage of CMV-IgM⁺ in MDA5⁺DM and MDA5⁻ IIM patients; CMV-IgM⁺ rates were increased in MDA5⁺ DM patients compared with MDA5⁻ IIM patients (13.5% vs. 4.3%, p = 0.019). (C) The percentage of recent CMV infection. Recent CMV infection rates were increased in MDA5⁺ DM compared with MDA5⁻ IIM patients (19.1% vs. 7.0%, p = 0.009). (D) The percentage of anti-MDA5-ab in IIM patients with and without CMV-IgM⁺. The MDA5⁺ rates were 70.6% in CMV-IgM⁺ patients and 41.2% in CMV-IgM⁻ patients (p = 0.019).